Recent

% | $
Quotes you view appear here for quick access.

InterOil Corporation Message Board

bucks_and_balls 14 posts  |  Last Activity: Feb 4, 2016 3:31 PM Member since: Nov 1, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bucks_and_balls bucks_and_balls Feb 4, 2016 3:31 PM Flag

    miraculous

  • bucks_and_balls bucks_and_balls Jan 26, 2016 7:49 PM Flag

    New Bioinvest Med Tech Stock Letter - Met with ZIOP Mgt Team - 2016 Will See Clinical Data & Multiple Trials Launched - Expect more partnerships this yr - ZIOP is a BUY under 12 with a TARGET PRICE of 20
    ZIOP – 2016 Will See Clinical Data & Multiple Trials Launched
    We saw its presentation and met separately with ZIOP’s management team at the JP Morgan conference and came away impressed with their clinical development plans for 2016. The most advanced trials are the two evaluating the powerful immune cytokine, IL-12, against the highly lethal brain cancer, recurrent glioblastoma (GBM) and breast cancer. The GMB trial has already delivered data showing that neurotoxicity is both minimal and manageable since IL-12 expression is regulated by ZIOP’s RheoSwitch. Data will be presented in early June at ASCO and given the very short life expectancy of GMB patients we may even see survival data. The trial in breast cancer patients is designed to assess IL-12’s ability to impact disease progression. In addition, the trial should confirm an increase in memory T cells – a a sign that the patient’s immune system is fighting the cancer. A third IL-12 trial will start later this year and will combine the IL-12 gene therapywith a checkpoint inhibitor, possibly against GBM, – potentially highly efficacious combination. Preclinical data supporting the combination will be presented at the American Society of Gene and Cell Therapy meeting in early May.
    In 2016, ZIOP will start two CD19-CAR T cell trials, with the first one incorporating a second-generation Sleeping Beauty in patients who have had a hematopoietic stem cell transplant for advanced B-cell lymphoma or leukemia. The second trial will use CD19-CAR T cells incorporating a lentiviral vector to treat myeloid malignancies. ZIOP will also begin a trial of allogeneic natural killer cells (derived from umbilical cord blood) to treat acute myeloid leukemia, in 2016. This was one of Dr. Cooper’s pet research projects at MD Anderson.
    ZIOP is positioned for a busy and productive 2016 in the clinic. In addition, to the six trials discussed above, their partner Merck KGa will have two other trials up and running in 2016 using ZIOP’s second-generation gene therapy technology. We expect the company to sign additional corporate partners during the year which would add further clinical development drug candidates. In our view, the IL-12 program to treat GBM could serve as a significant catalyst with potential survival data at ASCO. Positive GBM data could move the drug into a pivotal trial by year end.
    ZIOP is a BUY under 12 with a TARGET PRICE of 20

  • New Griffin Report-six trials will test its IL-12 gene therapy,CD-19 CAR T cells, and NK cells against distinct types of cancer. BUY $21.00 Target Price

    Griffin Securities

    Stock Symbol NYSE: ZIOP

    Current Price $5.86

    12 mos. Target Price $21.00

    Market Cap $767.1 mln

    Shares O/S 130.9 mln

    Avg Daily Vol. (3 mos.) 2,963,054 shs.

    Ziopharm BUY

    Company Update : Biotechnology

    The Trials of 2016

    Ziopharm laid out its clinical development plans last week in

    San Francisco. In all, six trials will test its IL-12 gene therapy,

    CD-19 CAR T cells, and NK cells against distinct types of cancer.

    Three IL-12 gene therapy studies: Two are evaluating the

    immune stimulant against the highly lethal brain cancer recurrent

    glioblastoma and breast cancer. The former study has already

    yielded encouraging data showing that neurotoxicity is minimal

    and manageable since expression of the cytokine is regulated by

    Intrexon’s RheoSwitch®. Data will be presented in early June at

    the ASCO annual meeting. The latter trial, which is designed to

    assess IL-12’s ability to impact disease progression, should see

    patient enrollment accelerate now that toxicities have been well

    controlled in the first of seven planned dosage strengths. Besides

    improved progression-free survival, the trial should confirm an

    increase in memory T cells that indicate the patient’s immune

    system is engaged in fighting the cancer. The third clinical study,

    which will start later this year, will combine the IL-12 gene therapy

    with a checkpoint inhibitor, possibly against glioblastoma. The

    combination has exciting potential, since the cytokine stimulates

    the immune system and checkpoint inhibitors remove a tumor’s

    cloaking device to evade immune attack. Related preclinical data

    will be presented at the American Society of Gene and Cell

    Therapy meeting in early May.

    Two CD19-CAR T cell trials: One is testing a cell therapy

    prepared with the Sleeping Beauty technology to have improved

    persistence and anti-tumor activity. The study involves patients

    who have had a hematopoietic stem cell transplant for advanced

    B-cell lymphoma or leukemia. The second trial, which will

    assess CD19-CAR T cells, prepared with a lentiviral vector

    against myeloid malignancies, should commence later this year.

    Preclinical data has shown that the cells express the chimeric

    antigen receptor, are cytotoxic, and produce interferon-γ.

    One NK cell study: Ziopharm will initiate a trial of allogeneic

    natural killer cells (derived from umbilical cord blood) to treat acute

    myeloid leukemia, a disease primarily of the elderly. Research at

    MD Anderson and elsewhere has yielded results suggesting this

    treatment is both efficacious and safe.

    Preparations for future studies point to a busy 2017. The

    Company plans to initiate clinical trials of IL-12 for a pediatric

    cancer, a cytokine-expressing CD19-CAR T cell for leukemia/

    lymphoma, and a combination NK cell/IL-12 therapy for brain

    cancer next year. Progress on these, plus clinical data from the

    2016 trials, augurs well for ZIOP shares

    .

    We are affirming our BUY rating and $21 price target.

  • Reply to

    SB 3.0

    by biotrader_1 Jan 20, 2016 9:20 PM
    bucks_and_balls bucks_and_balls Jan 23, 2016 3:08 PM Flag

    Cooper in Dallas said the results will be many times better than the quality SB 1.0 results

  • Reply to

    Griffin research report

    by abbrainmaker Jan 19, 2016 12:50 PM
    bucks_and_balls bucks_and_balls Jan 19, 2016 10:14 PM Flag

    New Griffin Report-six trials will test its IL-12 gene therapy,CD-19 CAR T cells, and NK cells against distinct types of cancer. BUY $21.00 Target Price

    Griffin Securities

    Stock Symbol NYSE: ZIOP

    Current Price $5.86

    12 mos. Target Price $21.00

    Market Cap $767.1 mln

    Shares O/S 130.9 mln

    Avg Daily Vol. (3 mos.) 2,963,054 shs.

    Ziopharm BUY

    Company Update : Biotechnology

    The Trials of 2016

    Ziopharm laid out its clinical development plans last week in

    San Francisco. In all, six trials will test its IL-12 gene therapy,

    CD-19 CAR T cells, and NK cells against distinct types of cancer.

    Three IL-12 gene therapy studies: Two are evaluating the

    immune stimulant against the highly lethal brain cancer recurrent

    glioblastoma and breast cancer. The former study has already

    yielded encouraging data showing that neurotoxicity is minimal

    and manageable since expression of the cytokine is regulated by

    Intrexon’s RheoSwitch®. Data will be presented in early June at

    the ASCO annual meeting. The latter trial, which is designed to

    assess IL-12’s ability to impact disease progression, should see

    patient enrollment accelerate now that toxicities have been well

    controlled in the first of seven planned dosage strengths. Besides

    improved progression-free survival, the trial should confirm an

    increase in memory T cells that indicate the patient’s immune

    system is engaged in fighting the cancer. The third clinical study,

    which will start later this year, will combine the IL-12 gene therapy

    with a checkpoint inhibitor, possibly against glioblastoma. The

    combination has exciting potential, since the cytokine stimulates

    the immune system and checkpoint inhibitors remove a tumor’s

    cloaking device to evade immune attack. Related preclinical data

    will be presented at the American Society of Gene and Cell

    Therapy meeting in early May.

    Two CD19-CAR T cell trials: One is testing a cell therapy

    prepared with the Sleeping Beauty technology to have improved

    persistence and anti-tumor activity. The study involves patients

    who have had a hematopoietic stem cell transplant for advanced

    B-cell lymphoma or leukemia. The second trial, which will

    assess CD19-CAR T cells, prepared with a lentiviral vector

    against myeloid malignancies, should commence later this year.

    Preclinical data has shown that the cells express the chimeric

    antigen receptor, are cytotoxic, and produce interferon-γ.

    One NK cell study: Ziopharm will initiate a trial of allogeneic

    natural killer cells (derived from umbilical cord blood) to treat acute

    myeloid leukemia, a disease primarily of the elderly. Research at

    MD Anderson and elsewhere has yielded results suggesting this

    treatment is both efficacious and safe.

    Preparations for future studies point to a busy 2017. The

    Company plans to initiate clinical trials of IL-12 for a pediatric

    cancer, a cytokine-expressing CD19-CAR T cell for leukemia/

    lymphoma, and a combination NK cell/IL-12 therapy for brain

    cancer next year. Progress on these, plus clinical data from the

    2016 trials, augurs well for ZIOP shares

    .

    We are affirming our BUY rating and $21 price target.

  • Reply to

    I Give ZIOP a BUY Rating.................

    by georgeybushky Jan 18, 2016 7:26 PM
    bucks_and_balls bucks_and_balls Jan 19, 2016 11:43 AM Flag

    Please paste your buy transaction proof

  • bucks_and_balls bucks_and_balls Dec 15, 2015 11:16 AM Flag

    Hope its cooper without kirk

  • bucks_and_balls bucks_and_balls Dec 15, 2015 11:14 AM Flag

    Me too....will be back to 14 by Jan 20

  • bucks_and_balls bucks_and_balls Dec 9, 2015 7:10 PM Flag

    Agree - they round trip this up and down but this company is a goner. Kirk is selling - 2 companies interested. Done deal soon..with Merck failure with THLD old drugs and launching as immunotherapy as their new lead program they need ZIOP.

  • bucks_and_balls bucks_and_balls Dec 9, 2015 7:07 PM Flag

    What is exciting is the newer version. Cooper told 10 of us that the 8/8 efficacy and 7/8 still in complete remission is the early sleeping beauty but the new one for the new trial is much better more powerful

  • bucks_and_balls bucks_and_balls Nov 25, 2015 6:20 PM Flag

    KITE and JUNO need the Rheo Switch. I think rumor of IL12 deal by JP Morgan will be either KITE BMY JUNO ROCHE OR GSK. Will rocket ZIOP to $20 IMO

  • bucks_and_balls bucks_and_balls Nov 25, 2015 6:17 PM Flag

    ZIOP I/R says the IL-12 breast data Ph 2 coming Dec 8 at San Antonio Breast is even better than Glioma...And we get the newer Sleeping Beauty blood cancer data at ASH Dec 5-7 which supposedly is 100 times more powerful than old sleeping beauty shorts know but much safer and cheaper than KITE JUNO therapy and we can turn on and off and up and down regulate they cant they can only "kill" with switch, Stay tuned for runs to the 20s

  • bucks_and_balls bucks_and_balls Nov 25, 2015 6:15 PM Flag

    ASH could be huge. Love how ZIOP traded today. New highs by ASH. $20 by JP Morgan in Jan

IOC
27.95+2.16(+8.38%)11:50 AMEST